Int J Clin Pharm. 2011 Dec;33(6):895-7. doi: 10.1007/s11096-011-9565-3.
Decisions about spending on medicines occur at different levels in the Australian health care system. This commentary describes the role of economic evaluation at the institutional (public hospital) level. In contrast to the decisions taken at the level of Federal subsidy (listing on the Pharmaceutical Benefits Scheme) formal pharmacoeonomic data analyses are usually not available, and arguably often not relevant to decision making within the public hospital setting. Future research is needed to develop and explore models of best practice and how to incorporate pharmacoeconomic evidence into local decisions.
关于药品支出的决策发生在澳大利亚医疗保健系统的不同层面。本评论描述了经济评估在机构（公立医院）层面的作用。与联邦补贴层面（列入药品福利计划）的决策不同，通常无法获得正式的药物经济学数据分析，而且可以说，这些数据对于公立医院环境中的决策往往不相关。需要开展未来研究，以制定和探索最佳实践模式，并探讨如何将药物经济学证据纳入当地决策。
